首页> 外文期刊>Journal of viral hepatitis. >Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.
【24h】

Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.

机译:Vogt-Koyanagi-Harada病与干扰素α-2b/利巴韦林联合治疗有关。

获取原文
获取原文并翻译 | 示例
       

摘要

The complex immunological effects of interferon and ribavirin therapy (IFN/R) in hepatitis C virus (HCV) may also exacerbate or trigger the de novo development of autoimmunity. We report the first case of IFN/R therapy associated with Vogt-Koyanagi-Harada disease, a T-cell-mediated autoimmune response to melanocytes. This condition, which has characteristic ocular, neurological and integumentary findings, elicits a systemic prodrome that may mimic side-effect profile and delay of IFN or mask its recognition. We discuss this disease in the context of the known immunomodulatory effects of IFN-alpha and ribavirin and suggest potential mechanistic explanations for the association.
机译:干扰素和利巴韦林疗法(IFN / R)对丙型肝炎病毒(HCV)的复杂免疫学作用也可能加剧或触发自身免疫的从头发展。我们报道了第一例与Vogt-Koyanagi-Harada病有关的IFN / R治疗,这是T细胞介导的对黑素细胞的自身免疫反应。这种具有眼,神经和外皮特征的疾病会引起全身性前驱症状,其可能模拟IFN的副作用和延迟或掩盖其识别。我们在已知的干扰素-α和利巴韦林的免疫调节作用的背景下讨论这种疾病,并建议潜在的机制解释的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号